Dr Brad Gessner | VP for Scientific Affairs at AMP, Faculty at U. Maryland/Centers for Vaccine Development & VP and Director, Global Pneumococcal
Pfizer | United States

Dr Brad Gessner, VP for Scientific Affairs at AMP, Faculty at U. Maryland/Centers for Vaccine Development & VP and Director, Global Pneumococcal, Pfizer

Bradford D. Gessner is Scientific Director and Chief Epidemiologist of the Paris-based Agence de Médicine Préventive (AMP). In this role, he is responsible for the oversight of AMP’s scientific studies and publications.

He is also at the Faculty at U. Maryland/Centers for Vaccine Development 3. VP and Director of GLobal Pneumococcal Vaccines at Pfizer (where he spends most of my time currently). Dr Gessner has participated in several large clinical trials, authored more than 100 peer-reviewed journal articles, and served as an expert consultant to the WHO on panels dealing with meningitis, yellow fever, and respiratory infections, including infuenza. His areas of expertise include vaccine-preventable diseases, pediatric epidemiology, polysaccharide encapsulated organisms, and respiratory syncytial virus infection (RSV). Previously, Dr Gessner founded and directed the Maternal and Child Health (MCH) Epidemiology Unit within the Alaska Division of Public Health. He also worked as a staff pediatrician at the Anchorage Neighborhood Health Center. In 1993 he completed an Epidemic Intelligence Service fellowship with the U.S. Centers for Disease Control and Prevention (CDC, USA), a two-year, post-graduate on-the-job training program for health professionals interested in applied epidemiology. Dr Gessner earned his BA from Dartmouth College and his MD from the University of Florida. After completing his pediatric residency at the University of Colorado, he obtained his MPH and completed a Preventive Medicine residency at the University of Washington. He currently serves on the faculty of the University of Washington School of Medicine and the University of Alaska Anchorage (USA).

Appearances:



DC Co-conference Day 2 April 4 @ 11:40

Can we use moderately effective vaccines for safe public use? Using Dengue as an example

back to speakers